• 主页
  • 查找结果
  • Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.

Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.

Journal of the American College of Cardiology (2015-02-14)
Frédéric Perros, Benoît Ranchoux, Mohamed Izikki, Sana Bentebbal, Chris Happé, Fabrice Antigny, Philippe Jourdon, Peter Dorfmüller, Florence Lecerf, Elie Fadel, Gerald Simonneau, Marc Humbert, Harm Jan Bogaard, Saadia Eddahibi
摘要

Endothelial cell (EC) dysfunction plays a central role in the pathogenesis of pulmonary arterial hypertension (PAH), promoting vasoconstriction, smooth muscle proliferation, and inflammation. This study sought to test the hypothesis that nebivolol, a β1-antagonist and β2,3-agonist, may improve PAH and reverse the PAH-related phenotype of pulmonary ECs (P-EC). We compared the effects of nebivolol with metoprolol, a first-generation β1-selective β-blocker, on human cultured PAH and control P-EC proliferation, vasoactive and proinflammatory factor production, and crosstalk with PA smooth muscle cells. We assessed the effects of both β-blockers in precontracted PA rings. We also compared the effects of both β-blockers in experimental PAH. PAH P-ECs overexpressed the proinflammatory mediators interleukin-6 and monocyte chemoattractant protein-1, fibroblast growth factor-2, and the potent vasoconstrictive agent endothelin-1 as compared with control cells. This pathological phenotype was corrected by nebivolol but not metoprolol in a dose-dependent fashion. We confirmed that PAH P-EC proliferate more than control cells and stimulate more PA smooth muscle cell mitosis, a growth abnormality that was normalized by nebivolol but not by metoprolol. Nebivolol but not metoprolol induced endothelium-dependent and nitric oxide-dependent relaxation of PA. Nebivolol was more potent than metoprolol in improving cardiac function, pulmonary vascular remodeling, and inflammation of rats with monocrotaline-induced pulmonary hypertension. Nebivolol could be a promising option for the management of PAH, improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function. Until clinical studies are undertaken, however, routine use of β-blockers in PAH cannot be recommended.

材料
货号
品牌
产品描述

Sigma-Aldrich
羟乙基哌嗪乙硫磺酸, ≥99.5% (titration)
Sigma-Aldrich
羟乙基哌嗪乙硫磺酸, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
HEPES缓冲溶液, 1 M in H2O
Sigma-Aldrich
L-谷氨酰胺, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
L-谷氨酰胺, ReagentPlus®, ≥99% (HPLC)
SAFC
羟乙基哌嗪乙硫磺酸
SAFC
L-谷氨酰胺
Sigma-Aldrich
羟乙基哌嗪乙硫磺酸, BioUltra, for molecular biology, ≥99.5% (T)
SAFC
羟乙基哌嗪乙硫磺酸
Sigma-Aldrich
L-谷氨酰胺, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
羟乙基哌嗪乙硫磺酸, BioXtra, pH 5.0-6.5 (1 M in H2O), ≥99.5% (titration)
Sigma-Aldrich
羟乙基哌嗪乙硫磺酸, BioXtra, suitable for mouse embryo cell culture, ≥99.5% (titration)
Sigma-Aldrich
L-谷氨酰胺, γ-irradiated, BioXtra, suitable for cell culture
Supelco
L-谷氨酰胺, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-谷氨酰胺, certified reference material, TraceCERT®
Sigma-Aldrich
羟乙基哌嗪乙硫磺酸, anhydrous, free-flowing, Redi-Dri, ≥99.5%
Sigma-Aldrich
L-谷氨酰胺
Supelco
HEPES, Pharmaceutical Secondary Standard; Certified Reference Material